Learning from Pfizer Acquisition. Regeneron to Fight Zika and More

Pfizer accepted to pay $14 billion in cash to acquire Medivation.

It is important for investors to know what Pfizer is after with regard to this acquisition so that investors could sense the current deep-pocketed biopharmaceutical firms’ preferences in selecting their takeover targets.

Recognizing the facts behind Pfizer’s decision could also protect investors from being mislead by negative bloggers who, while serving their own agendas, deceive others, making them miss great investment opportunities.

Indeed, negative campaigns trying to diminish the values of immunotherapy breakthrough drugs are highly active and are being used intelligently through comments on . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.